CompletedPhase 4Results posted

Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease

Effects of Memantine on the Magnetic Resonance Spectroscopy (MRS) Measures of Neuronal Integrity in Subjects at Risk for Alzheimer's Disease

Lead sponsor

NYU Langone Health

Asset

Memantine

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Family history of Alzheimer’s disease required•MRI contraindications excluded

Primary endpoint

•N-acetylaspartate

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDNAM-MD-68

NCT IDNCT00933608

Timeline

Milestones

Study start2009-07 (month precision)

Study first posted2009-07-07estimated

Primary completion2011-09actual (month precision)

Study completion2011-09actual (month precision)

Last update posted2014-10-21estimated

Results first posted2014-10-21estimated

Assets

Drug assets

Memantine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

Maximum age90 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•presence of subjective memory complaints without objective evidence of impaired cognition

•family history of Alzheimer's disease

Exclusion criteria

•major depression

•Parkinson's disease

•stroke

•seizures

•uncontrolled diabetes or hypertension

•current benzodiazepine use

•substance abuse

•contraindication for MRI

•contraindications for memantine

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Neuroimaging

2 endpoints

Primary/protocol endpoint

N-acetylaspartate

Time frame:baseline (pre-treatment) and 4 months (post-treatment)

change from baseline, improvement

Primary/registry result

N-acetylaspartate

Time frame:baseline (pre-treatment) and 4 months (post-treatment)

change from baseline, improvement

Posted result

Group	Value (mean), NAA/creatine Ratio	Standard deviation
Memantinepre-treatmentn=4 Participants	1.35	.38
post-treatmentn=4 Participants	1.58	.005
Placebopre-treatmentn=9 Participants	1.86	.43
post-treatmentn=9 Participants	1.26	.49

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.